P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST-ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST-ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST-ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST-ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN

Bibliographic Details
Main Authors:	C. Vallejo, I. García, F. Sanchez Guijo, M. Cuesta, C. Solano, A. Sampol, T. Torrado, M. Vendranas, M. Marigil
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846232.58961.88

Similar Items

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
by: D. wang, et al.
Published: (2022-06-01)

Eltion Meka and Stefano Bianchini: The Challenges of Democratization and Reconciliation in the Post-Yugoslav Space
by: Sotiropoulos Dimitri A.
Published: (2021-12-01)

RIC VS MAC IN ALLO-HSCT FOR CHILDHOOD MYELODYSPLASTIC SYNDROME
by: Elena Morozova, et al.
Published: (2023-12-01)

P1632: PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY
by: S. Chèze, et al.
Published: (2022-06-01)

Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag
by: Cen Tang, et al.
Published: (2018-08-01)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
by: Ming Sun, et al.
Published: (2023-08-01)

Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
by: Rashin Mohseni, et al.
Published: (2023-09-01)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
by: Shengnan Zhou, et al.
Published: (2023-08-01)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
by: Mahinbanu Mammadli, et al.
Published: (2021-04-01)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
by: Raffaella Greco, et al.
Published: (2021-03-01)

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
by: Emma C. Morris, et al.
Published: (2019-10-01)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
by: J. M. Cerezo-Martin, et al.
Published: (2022-06-01)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
by: Luxiang Wang, et al.
Published: (2023-07-01)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
by: Wen-hui Wang, et al.
Published: (2023-01-01)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
by: Mahinbanu Mammadli, et al.
Published: (2020-11-01)

A rare case of hereditary spherocytosis treated with allogenic HSCT
by: Juhi Mehrotra, et al.
Published: (2022-01-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

Dangers resulting from DNA profiling of biological materials derived from patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with regard to forensic genetic analysis
by: Renata Jacewicz, et al.
Published: (2016-07-01)

Eltrombopag for thrombocytopenia following pediatric allogeneic hematopoietic stem cell transplantation
by: A. Akyay, et al.
Published: (2020-10-01)

S245: ALTERATION OF BONE MARROW NICHE BY ALLOGENEIC IMMUNE REACTION AFTER HSCT
by: M Kimura, et al.
Published: (2022-06-01)

S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS
by: S. Harbi, et al.
Published: (2022-06-01)

CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
by: M. I. Zaraiski
Published: (2014-07-01)

Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature
by: Can Chen, et al.
Published: (2024-01-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
by: Mohammad S Hossain, et al.
Published: (2017-01-01)

Environmental pathways affecting gene expression (E.PAGE) as an R package to predict gene–environment associations
by: Sachin Muralidharan, et al.
Published: (2022-11-01)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
by: Semra Aydin, et al.
Published: (2020-10-01)

Autoimmune complication post HSCT in a case of MDS with monosomy 7
by: Zainab M. Golwala, et al.
Published: (2017-01-01)

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
by: Samip Master, et al.
Published: (2018-03-01)

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review
by: Nicole Sonneveld, et al.
Published: (2023-07-01)

6.837 Computer Graphics, Fall 2003
by: Durand, Frédo, et al.
Published: (2003)

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
by: Süreyya Yiğit Kaya, et al.
Published: (2023-01-01)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
by: Megumi Matsumoto, et al.
Published: (2022-08-01)

Application of metagenomic next-generation sequencing in the clinical diagnosis of infectious diseases after allo-HSCT: a single-center analysis
by: Hailong Yuan, et al.
Published: (2024-03-01)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
by: Zhangjie Chen, et al.
Published: (2023-08-01)

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
by: Jinhua Ren, et al.
Published: (2023-03-01)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
by: Shupeng Wen, et al.
Published: (2018-11-01)

Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation (HSCT) in Acute Myeloid Leukemia
by: Arnon Nagler
Published: (2022-10-01)

Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2)
by: Enrico Morello, et al.
Published: (2022-08-01)

The Effect of PGF2α Injection on Post-Thaw Motility in Sperm of Nubian Goats
by: Aswadi Aswadi, et al.
Published: (2021-02-01)